European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“We are pleased to announce the publication of an important multinational trial by Lisa M. Wintner, PhD et al. in The Lancet Oncology showing that clinician access to EORTC patient – reported outcome (PRO) data markedly improves the reliability of cancer treatment side effect evaluation.
The study, conducted across 11 hospitals in ten countries, found significantly higher inter – rater reliability for most symptomatic adverse events when providers could see PRO data alongside their assessments. This supports a more patient – centred approach in clinical trials and everyday oncology care.”
Read the full news release
More posts featuring European Organisation for Research and Treatment of Cancer